Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Completed · Phase 3 · NCT03187769
Conditions: Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
At a glance
- Research payments reported, 2025
- $215,040
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 426
About the trial
- Sponsor
- Alkermes, Inc.
- Tested
- ALKS 3831 (drug), Olanzapine (drug)
- Dates
- Started 2017-06-08; completion 2022-01-03
- Results posted
- Yes
This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
From ClinicalTrials.gov, last updated 2023-01-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Alkermes, Inc. reported $215,040 in research payments for this study in 2025 (1 payments).
Products named: Lybalvi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- Vanguard Research Group $215,040
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.